HDAC6型
化学
HDAC1型
体内
乙酰化
药理学
IC50型
体外
组蛋白脱乙酰基酶
癌症研究
生物化学
组蛋白
生物
基因
生物技术
作者
Xi Xu,Di Zhang,Tengteng Zhao,Min Wang,Yu Liu,Qianming Du,Junping Kou,Zhiyu Li,Jinlei Bian
标识
DOI:10.1016/j.ejmech.2022.114228
摘要
A series of novel biphenyl-based scaffold derivatives were identified as selective histone deacetylase 6 (HDAC6) inhibitors through an in-house compound library screening approach. The biological evaluation indicated that most of target compounds exhibited moderate to good inhibitory activity and selectivity against HDAC6. Especially, compound C10 was identified as a potent and highly selective HDACs inhibitor, with HDAC1 IC50 value of 3600 nM, HDAC6 IC50 value of 23 nM, and the HDAC1/6 selectivity index of 157. Moreover, C10 displayed robust anti-proliferative activity, induced cancer cells apoptosis, increased the level of acetylated α-tubulin and inhibited cancer cells migration in vitro. C10 showed significant antitumor efficacy (TGI: 75%) in CT26 colon carcinoma xenograft model in mice with no considerable toxicity in vivo. More importantly, C10 could also activate antitumor immunity so as to synergistically exert antitumor effects in vivo. Overall, our findings have provided a new avenue for design, development and investigation into the mechanism underlying the antitumor efficacy of selective HDAC6 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI